Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 1/20 | 0.34 |
| ▸ | TP53 | P04637 | 1/20 | 0.34 |
| ▸ | RAB9A | P51151 | 1/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.34 |
| ▸ | GPR84 | Q9NQS5 | 2/20 | 0.32 |
| ▸ | CNR1 | P21554 | 1/20 | 0.32 |
| ▸ | ADCY8 | P40145 | 1/20 | 0.31 |
| ▸ | ADCY1 | Q08828 | 1/20 | 0.31 |
| ▸ | NR3C1 | P04150 | 1/20 | 0.31 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.31 |
| ▸ | TOP1 | P11387 | 1/20 | 0.30 |
| ▸ | AR | P10275 | 1/20 | 0.30 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.30 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20845319 | 0.93 | GP6 (0.33) | NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL20845323 | 0.91 | MEN1 (0.34) | NPC1TP53RAB9ASMN1; SMN2ADORA2A | |
| SCHEMBL20845325 | 0.87 | MEN1 (0.36) | NPC1RAB9ASMN1; SMN2GPR84ADORA2A | |
| SCHEMBL20845322 | 0.86 | MEN1 (0.34) | SMN1; SMN2ADORA2AADORA1 | |
| SCHEMBL20845141 | 0.86 | MEN1 (0.37) | NPC1RAB9ASMN1; SMN2GPR84ADORA2A | |
| SCHEMBL20845314 | 0.84 | CYP11B1 (0.41) | NPC1TP53RAB9ASMN1; SMN2 | |
| SCHEMBL20845150 | 0.83 | NPC1 (0.36) | NPC1TP53RAB9ASMN1; SMN2ADCY8 | |
| SCHEMBL20845239 | 0.81 | MEN1 (0.42) | SMN1; SMN2ADORA2AADORA1 | |
| SCHEMBL20845137 | 0.78 | MEN1 (0.37) | GPR84ADORA2AADORA1 | |
| SCHEMBL20222671 | 0.78 | MEN1 (0.47) | NPC1RAB9ASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20190092745-A1 | COMPOUND AND ORGANIC ELECTRONIC DEVICE USING THE SAME | NICHEM FINE TECHNOLOGY CO., LTD. (TW) | 2019-03-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190092745-A1 | COMPOUND AND ORGANIC ELECTRONIC DEVICE USING THE SAME | SCO2, AOX1, ORC3 | NPC1 4683/4885TP53 3777/4885RAB9A 635/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.